Astrana Health (ASTH) stock continued its upward trajectory, soaring 11.84% in pre-market trading on Friday, building on the previous day's 5.45% gain. This surge comes in the wake of the company's mixed second-quarter results for 2025, demonstrating strong investor confidence in the healthcare provider's growth prospects.

The company's Q2 earnings report, released earlier this week, showed a 34.7% year-over-year increase in revenue to $654.81 million, surpassing analyst expectations of $638.32 million. However, Astrana Health's adjusted earnings per share (EPS) of $0.19 fell short of the anticipated $0.36, marking a decrease from the $0.40 EPS reported in the same quarter last year. Despite this earnings miss, investors appear to be focusing on the company's robust revenue growth and positive forward-looking statements.

Wall Street's bullish stance on Astrana Health remains intact, with Truist Financial reiterating its Buy rating on the stock. The average analyst recommendation stands at "buy," with 8 out of 11 analysts recommending either "strong buy" or "buy." The median 12-month price target of $46.00 represents a potential upside of over 50% from recent trading levels, further fueling investor optimism. Additionally, Astrana Health's reaffirmation of its full-year 2025 guidance, which includes the impact of the recently completed Prospect Health acquisition, suggests confidence in the company's ability to deliver long-term value despite short-term earnings pressures.